India's Concord Biotech rises on US FDA approval for Mycophenolate Mofetil

Concord Biotech

03/06/2026 05:53

** Shares of Concord Biotech CONB.NS rise 5.6% to 1,231 rupees, set to gain for a third consecutive session, if current trend holds 
** The pharmaceuticals company gets an approval from U.S. Food and Drug Administration for Mycophenolate Mofetil for oral suspension USP
** Mycophenolate Mofetil is indicated for prophylaxis of organ rejection during allogeneic kidney, heart or liver transplants
** Trading vols nearly 9x the 30-day average at 2.5 million shares so far
** YTD, Concord stock down ~9%


 (Reporting by Vijay Malkar)
 ((VijayDattaram.Malkar@thomsonreuters.com;))